Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Notes Payables (2016 - 2017)

Gyre Therapeutics (GYRE) has disclosed Notes Payables for 3 consecutive years, with $5.1 million as the latest value for Q4 2017.

  • On a quarterly basis, Notes Payables fell 73.79% to $5.1 million in Q4 2017 year-over-year; TTM through Dec 2017 was $5.1 million, a 73.79% decrease, with the full-year FY2017 number at $5.1 million, down 73.79% from a year prior.
  • Notes Payables was $5.1 million for Q4 2017 at Gyre Therapeutics, down from $5.5 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $34.8 million in Q3 2015 to a low of $5.1 million in Q4 2017.
  • A 3-year average of $20.8 million and a median of $24.5 million in 2016 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: decreased 14.69% in 2016, then tumbled 81.5% in 2017.
  • Gyre Therapeutics' Notes Payables stood at $33.7 million in 2015, then crashed by 42.5% to $19.4 million in 2016, then crashed by 73.79% to $5.1 million in 2017.
  • Per Business Quant, the three most recent readings for GYRE's Notes Payables are $5.1 million (Q4 2017), $5.5 million (Q3 2017), and $5.8 million (Q2 2017).